| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| ln Vitro |
At doses as low as 0.5 μg/mL, mitoguazone competes with transcription factors for spermidine production. mitochondrial respiration and transcribed protein synthesis at 30 μg/mL or more [1]. Mitoguazone's capacity to cause cell irradiation by blocking the polyamine pathway was assessed in 2015 using scaffolded cadaver lines (MPC 3) and lines Raji, Ramos, and Daudi. Mitoguazone causes p53-independent programmed cell death in the human breast cancer MCF7 cell line and induces apoptosis in all human cadaveric cell lines in a concentration- and time-dependent manner [2].
|
|---|---|
| ln Vivo |
Regardless of the trial period, the dosage AUC in mouse serum rose as a result of a decrease in mitoguazone's overall clearance. Furthermore, research has shown that medication levels in the kidneys, liver, and serum are higher in late stages of tumors when compared to early plasma without tumor control using specific instruments [5].
|
| References |
|
| Additional Infomation |
Mitoguazone is a hydrazone compound formed by the condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine. It possesses antitumor activity, induces apoptosis, and acts as an inhibitor of S-adenosylmethionine decarboxylase (EC 4.1.1.50). It is a hydrazone compound belonging to the guanidine class. Its function is related to methylglyoxal and aminoguanidine. It is the conjugate base of Mitoguazone (2+). Mitoguazone has been used in clinical trials for the treatment of lymphoma, HIV infection, and non-Hodgkin's lymphoma. Mitoguazone is a guanidine hydrazone with potential antitumor activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in polyamine synthesis, leading to reduced tumor cell proliferation, antimitochondrial effects, and induction of p53-independent apoptosis. Polyamines, particularly spermine and spermidine, are crucial for thymidine kinase production, DNA synthesis, and cell proliferation. (NCI04)
An antitumor drug, effective against myeloid leukemia in experimental animals. It is also an inhibitor of animal S-adenosylmethionine decarboxylase. |
| Molecular Formula |
C5H12N8
|
|---|---|
| Molecular Weight |
184.20238
|
| Exact Mass |
184.118
|
| CAS # |
459-86-9
|
| Related CAS # |
459-86-9 (free);7059-23-6 (dihydorchloride);
|
| PubChem CID |
5351154
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.55g/cm3
|
| Boiling Point |
436.6ºC at 760mmHg
|
| Flash Point |
217.8ºC
|
| Vapour Pressure |
7.99E-08mmHg at 25°C
|
| Index of Refraction |
1.692
|
| LogP |
0.696
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
264
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C/C(=N\N=C(N)N)/C=N/N=C(N)N
|
| InChi Key |
MXWHMTNPTTVWDM-NXOFHUPFSA-N
|
| InChi Code |
InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+
|
| Chemical Name |
2-[(E)-[(1E)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine
|
| Synonyms |
methylG; MeGAG; Mitoguazone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~271.44 mM)
DMSO : ~8.33 mg/mL (~45.22 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 4 mg/mL (21.72 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4289 mL | 27.1444 mL | 54.2888 mL | |
| 5 mM | 1.0858 mL | 5.4289 mL | 10.8578 mL | |
| 10 mM | 0.5429 mL | 2.7144 mL | 5.4289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
